Aminoglycosides are an important class of antibiotics for the treatment of aerobic, gram-negative bacteria (Pseudomonas, Acinetobacter, Enterobacter) and mycobacteria (Mycobacterium tuberculosis, M. avium), causes of serious co-infections in HIV-infected persons. Widespread use of aminoglycosides has been limited due to their toxicity (nephrotoxicity and ototoxicity) and inconvenient route of administration (intravenous or intramuscular);the adverse effects are related to plasma drug levels. For example, use of amikacin for first-line therapy is limited due to poor oral absorption, a short half-life, and serious renal and auditory toxicities which necessitate frequent intravenous administration, with concomitant monitoring of drug levels to ensure that the levels in plasma remain within a narrow therapeutic window.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research – Phase II (N44)
Project #
272201200021C-0-0-1
Application #
8570334
Study Section
Project Start
2012-09-12
Project End
2014-09-11
Budget Start
Budget End
Support Year
Fiscal Year
2012
Total Cost
$744,075
Indirect Cost
Name
Coordinated Program Development, LLC
Department
Type
DUNS #
832953678
City
Flemington
State
NJ
Country
United States
Zip Code
08822